Goldman Sachs’s Apellis Pharmaceuticals APLS Stock Holding History

Goldman Sachs’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-21,000	Closed	-$364K	–	6321
2025 Q2	$364K	Buy	+21,000	New	+$389K	﹤0.01%	5344
2023 Q4	–	Sell	-20,000	Closed	-$761K	–	5609
2023 Q3	$761K	Sell	20,000 -3,400	-15%	-$149K	﹤0.01%	4430
2023 Q2	$2.13M	Buy	+23,400	New	+$2.02M	﹤0.01%	3834
2020 Q4	–	Sell	-10,000	Closed	-$302K	–	5465
2020 Q3	$302K	Sell	10,000 -12,500	-56%	-$373K	﹤0.01%	4737
2020 Q2	$735K	Sell	22,500 -7,400	-25%	-$238K	﹤0.01%	4157
2020 Q1	$801K	Buy	29,900 +10,000	+50%	+$355K	﹤0.01%	3909
2019 Q4	$609K	Buy	+19,900	New	+$551K	﹤0.01%	4390

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's APLS Position: Q2 2026 in Review

Goldman Sachs sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,980,144 shares — an estimated $79.7M sold.

Goldman Sachs first reported a position in APLS in Q2 2018 and held it in 32 quarters. The position peaked at $79.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Goldman Sachs reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 1,980,144 Apellis Pharmaceuticals shares in Q2 2026, an estimated $79.7M.
Goldman Sachs first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 32 quarters.
Goldman Sachs's Apellis Pharmaceuticals position peaked at $79.7M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.